Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells

Journal of Immunology

Volumn 177, Issue 12, 2006, Pages 8730-8739

  Meyer Siegler, Katherine L ^a,b,f   Iczkowski, Kenneth A ^c,d   Leng, Lin ^e   Bucala, Richard ^e   Vera, Pedro L ^a,b  

^a Bay Pines Veterans Affairs Healthcare System Research and Development   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Bay Pines VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIGEN; CD74 ANTIGEN; CYTOKINE; HERMES ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 33845418379     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.12.8730     Document Type: Article

References (43)

1. Cordon-Cardo, C., and C. Prives. 1999. At the crossroads of inflammation and tumorigenesis. J. Exp. Med. 190: 1367-1370.
2. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867.
3. Platz, E. A., and A. M. DeMarzo. 2004. Epidemiology of inflammation and prostate cancer. J. Urol. 171: S36-S40.
4. Taylor, M. L., A. Mainous, G. 3rd, and B. J. Wells. 2005. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam. Med. 37: 506-512.
5. Dennis, L. K., and D. V. Dawson. 2002. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13: 72-79.
6. Kawakami, J., D. R. Siemens, and J. C. Nickel. 2004. Prostatitis and prostate cancer: implications for prostate cancer screening. Urology 64: 1075-1080.
7. Meyer-Siegler, K. L., M. A. Bellino, and M. Tannenbaum. 2002. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 94: 1449-1556.
8. Meyer-Siegler, K. L., K. A. Iczkowski, and P. L. Vera. 2005. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer 5: 73.
9. Baugh, J. A., and R. Bucala. 2002. Macrophage migration inhibitory factor. Crit. Care Med. 30: S27-S35.
10. Baugh, J. A., and S. C. Donnelly. 2003. Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J. Endocrinol 179: 15-23.
11. Mitchell, R. A., and R. Bucala. 2000. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin. Cancer Biol 10: 359-366.
12. Mitchell, R. A., H. Liao, J. Chesney, G. Fingerle-Rowson, J. Baugh, J. David, and R. Bucala. 2002. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. USA 99: 345-350.
13. Hudson, J. D., M. A. Shoaibi, R. Maestro, A. Carnero, G. J. Hannon, and D. H. Beach. 1999. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190: 1375-1382.
14. Henne, C., F. Schwenk, N. Koch, and P. Moller. 1995. Surface expression of the invariant chain (CD74) is independent of concomitant expression of major histocompatibility complex class II antigens. Immunology 84: 177-182.
15. Busch, R., C. H. Rinderknecht, S. Roh, A. W. Lee, J. J. Harding, T. Burster, T. M. Hornell, and F. D. Mellins. 2005. Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression. Immunol. Rev. 207: 242-260.
16. Wilson, K. M., M. O. Labeta, G. Pawelec, and N. Fernandez. 1993. Cell-surface expression of human histocompatibility leucocyte antigen (HLA) class II-associated invariant chain (CD74) does not always correlate with cell-surface expression of HLA class II molecules. Immunology 79: 331-335.
17. Meyer-Siegler, K. L., and P. L. Vera. 2005. Substance P induced changes in CD74 and CD44 in the rat bladder. J. Urol. 173: 615-620.
18. Ong, G. L., D. M. Goldenberg, H. J. Hansen, and Mattes, M. J. 1999. Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology 98: 296-302.
19. Leng, L., C. N. Metz, Y. Fang, J. Xu, S. Donnelly, J. Baugh, T. Delohery, Y. Chen, R. A. Mitchell, and Bucala, R. 2003. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197: 1467-1476.
20. Starlets, D., Y. Gore, I. Binsky, M. Haran, N. Harpaz, L. Shvidel, S. Becker-Herman, A. Berrebi, and I. Shachar. 2006. Cell surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107: 4807-4816.
21. Naujokas, M. F., M. Morin, M. S. Anderson, M. Peterson, and J. Miller. 1993. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 74: 257-268.
22. + T cell development. Immunity 3: 359-372.
23. Meyer-Siegler, K. L., E. C. Leifheit, and P. L. Vera. 2004. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 4; 34.
24. Iczkowski, K. A., C. G. Pantazis, and J. Collins. 1997. The loss of expression of CD44 standard and variant isoforms is related to prostatic carcinoma development and tumor progression. J. Urol. Pathol. 6: 119-129.
25. Agus, D. B., C. Cordon-Cardo, W. Fox, M. Drobnjak, A. Koff, D.W. Golde, and H. I. Scher. 1999. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl. Cancer Inst. 91: 1869-1876.
26. Zhong, X. B., Leng, L., Beitin, A., Chen, R., McDonald, C., Hsiao, B., Jenison, R. D., Kang, I., Park, S. H., Lee, et al. 2005. Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies. Nucleic Acids Res. 33: 121-129.
27. Bernhagen, J., Mitchell, R. A., Calandra, T., Voelter, W., Cerami, A., and Bucala, R. 1994. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor MIF. Biochemistry 33: 14144-14155.
28. Dios, A., R. A. Mitchell, B. Aljabari, J. Lubetsky, K. O'Connor, H. Liao, P. D. Senter, K. R. Manogue, E. Lolis, C. Metz, et al. 2002. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J. Med. Chem. 45: 2410-2416.
29. T) Methods. 24: 402-408.
30. Lue, H., R. Kleemann, T. Calandra, T. Roger, and J. Bernhagen. 2002. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect. 4: 449-460.
31. Al-Abed, Y., D. Dabideen, B. Aljabari, A. Valster, D. Messmer, M. Ochani, M. Tanovic, K. Ochani, M. Bacher, F. Nicoletti, et al. 2005. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis J. Biol Chem. 280: 36541-36544.
32. Fingerle-Rowson, G., P. Koch, R. Bikoff, X. Lin, C. N. Metz, F. S. Dhabhar, A. Meinhardt, and R. Bucala. 2003. Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am. J. Pathol. 162: 47-56.
33. Calandra, T., J. Bernhagen, C. N. Metz, L. A. Spiegel, M. Bacher, T. Donnelly, A. Cerami, and R. Bucala. 1995. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377: 68-71.
34. Roger, T., A. L., Chanson, M. Knaup-Reymond, and T. Calandra. 2005. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur. J. Immunol. 35: 3405-3413.
35. Mitchell, R. A., C. N. Metz, T. Peng, and R. Bucala. 1999. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J. Biol. Chem. 274: 18100-18106.
36. Iczkowski, K. A., S. Bai, and C. G. Pantazis. 2003. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. Anticancer Res. 23: 3129-3140.
37. Ren, Y., H. T. Tsui, R. T. Poon, I. O. Ng, Z. Li, Y. Chen, G. Jiang, C. Lau, W. C. Yu, M. Bacher, and S. T. Fan. 2003. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int. J. Cancer 107: 22-29.
38. Shimizu, T., R. Abe, H. Nakamura, A. Ohkawara, M. Suzuki, and J. Nishihira. 1999. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem. Biophys. Res. Commun. 264: 751-758.
39. Swant, J. D., B. E. Rendon, M. Symons, and R. A. Mitchell. 2005. Rho GTPase-dependent signaling is required for MIF-mediated expression of cyclin D1. J. Biol Chem. 280: 23066-23072.
40. Kleemann, R., A. Hausser, G. Geiger, R. Mischke, A. Burger-Kentischer, O. Flieger, F. J. Johannes, T. Roger, T. Calandra, A. Kapumiotu, et al. 2000. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408: 211-216.
41. Baumann, R., C. Casaulta, D. Simon, S. Conus, S. Yousefi, and H. U. Simon. 2003. Macrophage migration inhibitory factor delays apoptosis in neutrophils by inhibiting the mitochondria-dependent death pathway. FASEB J. 17: 2221-2230.
42. Xiao, D., D. Chinnappan, R. Pestell, C. Albanese, and H. C. Weber. 2005. Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells. Cancer Res. 65: 9934-9942.
43. Shiozawa, T., T. Miyamoto, H. Kashima, K. Nakayama, T. Nikaido, and I. Konishi. 2004. Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene 23: 8603-8610.